PMID: 6112842Jan 1, 1981Paper

Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?

Acta Psychiatrica Scandinavica
N Manos, J Gkiouzepas

Abstract

In a double-blind study of 100 chronic schizophrenic patients, withdrawal of antiparkinson (AP) medication showed that 44% of the 75 patients who constituted the placebo group (versus none of the patients on active AP medication), complained strongly of debilitating extrapyramidal symptoms (EPS) and another 22.6% (versus 8.7% of the patients on active AP medication), displayed disturbing psychotic symptomatology related to EPS. The authors discuss their findings in relation to the widely held view that AP medication may be safely withdrawn from chronic schizophrenics.

References

Jun 1, 1976·British Journal of Clinical Pharmacology·H A McClelland
Jan 1, 1975·Comprehensive Psychiatry·T Van Putten
Apr 1, 1972·Archives of General Psychiatry·C J Klett, E Caffey
Nov 1, 1971·Archives of General Psychiatry·P OrlovJ O Cole

❮ Previous
Next ❯

Citations

Aug 1, 1991·Journal of Clinical Pharmacology·M R Lavin, A Rifkin
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·J N Joyce
Mar 1, 1985·Acta Psychiatrica Scandinavica·M McInnis, H Petursson
Jun 1, 1984·Acta Psychiatrica Scandinavica·M McInnis, H Petursson
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Jun 2, 2012·Journal of Psychopharmacology·Julie Eve DesmaraisHoward C Margolese
Jul 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·A RifkinR Munne
Jan 1, 1989·The Journal of International Medical Research·M Lader

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.